The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy

被引:97
作者
Krijnen, JLM
Bogdanowicz, JFAT
Seldenrijk, CA
Mulder, PGH
vanderKwast, TH
机构
[1] ERASMUS UNIV ROTTERDAM, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS
[2] REINIER DE GRAAF HOSP, DEPT UROL, DELFT, NETHERLANDS
[3] REINIER DE GRAAF HOSP, DEPT PATHOL, DELFT, NETHERLANDS
关键词
prostatic neoplasms; neuroendocrinology; adenocarcinoma; endocrinology;
D O I
10.1097/00005392-199707000-00054
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the prognostic impact of neuroendocrine differentiation in prostate cancer with regard to the onset of endocrine therapy failure. Materials and Methods: A retrospective study was performed on 72 transurethral resection specimens from patients who subsequently underwent endocrine therapy for prostate cancer and were followed for 44 to 95 months. Progression-free interval was recorded. Distribution pattern and proportion of neuroendocrine cells were examined in transurethral resection specimens. Neuroendocrine cells were identified based on immunoreactivity for chromogranin A. Results: Of 32 patients with progressive disease 27 died of prostate cancer. Chromogranin A positive cells were found in 40 of the 72 prostate cancers (55%). In a Cox proportional hazards analysis neuroendocrine differentiation of the tumor showed a negative correlation with progression-free survival (p = 0.022), which proved to be independent of the Gleason score (p <0.001). Conclusions: Our results support the view that neuroendocrine differentiation in prostatic adenocarcinomas is a prognostic factor for progressive disease under subsequent endocrine therapy. This prognosticator acts independently of tumor grade.
引用
收藏
页码:171 / 174
页数:4
相关论文
共 25 条
[1]   PEPTIDE-HORMONEACTIVE AND SEROTONIN-IMMUNOREACTIVE TUMOR-CELLS IN CARCINOMA OF THE PROSTATE [J].
ABRAHAMSSON, PA ;
WADSTROM, LB ;
ALUMETS, J ;
FALKMER, S ;
GRIMELIUS, L .
PATHOLOGY RESEARCH AND PRACTICE, 1987, 182 (03) :298-307
[2]   THE COURSE OF NEURO-ENDOCRINE DIFFERENTIATION IN PROSTATIC CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY TESTING CHROMOGRANIN-A AS AN ENDOCRINE MARKER [J].
ABRAHAMSSON, PA ;
FALKMER, S ;
FALT, K ;
GRIMELIUS, L .
PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (03) :373-380
[3]  
APRIKIAN AG, 1993, CANCER, V71, P3952, DOI 10.1002/1097-0142(19930615)71:12<3952::AID-CNCR2820711226>3.0.CO
[4]  
2-X
[5]   TERMINAL NEUROENDOCRINE DIFFERENTIATION OF HUMAN PROSTATE CARCINOMA-CELLS IN RESPONSE TO INCREASED INTRACELLULAR CYCLIC-AMP [J].
BANG, YJ ;
PIRNIA, F ;
FANG, WG ;
KANG, WK ;
SARTOR, O ;
WHITESELL, L ;
HA, MJ ;
TSOKOS, M ;
SHEAHAN, MD ;
NGUYEN, P ;
NIKLINSKI, WT ;
MYERS, CE ;
TREPEL, JB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (12) :5330-5334
[6]   RELATION OF ENDOCRINE-PARACRINE CELLS TO CELL-PROLIFERATION IN NORMAL, HYPERPLASTIC, AND NEOPLASTIC HUMAN PROSTATE [J].
BONKHOFF, H ;
WERNERT, N ;
DHOM, G ;
REMBERGER, K .
PROSTATE, 1991, 19 (02) :91-98
[7]   ANDROGEN RECEPTOR STATUS IN ENDOCRINE-PARACRINE CELL-TYPES OF THE NORMAL, HYPERPLASTIC, AND NEOPLASTIC HUMAN PROSTATE [J].
BONKHOFF, H ;
STEIN, U ;
REMBERGER, K .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1993, 423 (04) :291-294
[8]  
Bubendorf L, 1996, J PATHOL, V178, P437, DOI 10.1002/(SICI)1096-9896(199604)178:4<437::AID-PATH484>3.0.CO
[9]  
2-4
[10]  
CATALONA WJ, 1994, NEW ENGL J MED, V331, P996